RAVE (2010) — Trial Summary

RAVE (2010): Rituximab was as effective as cyclophosphamide for the induction of remission in severe ANCA-associated vasculitis, with a similar safety profile during the first 6 months of treatment.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.